Neko Health, a health tech company, announced Wednesday that it raised $700 million in Series C funding, which it will use to support its expansion into the U.S.
The Swedish-based company’s flagship product is the Neko Health Scan, a health assessment that analyzes skin health, pre-diabetes risk and blood abnormalities. It also assesses risk factors linked to metabolic syndrome, stroke and heart attack. Patients go into a Neko Health clinic for a 60-minute visit to receive this scan, and patients have a consultation with a medical professional to discuss the results and next steps.
Neko’s Series C round was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD. It comes after a $260 million Series B round in January 2025.
“Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale,” said Bejul Somaia, global partner of Lightspeed Venture Partners, in a statement. “We believe this is one of the most important healthcare companies of our generation, and we’re proud to deepen our partnership as they continue to reimagine prevention.”
The funding will support expansion in the U.S., as well as continued growth in the U.K., the company said. Neko Health is first opening a clinic in New York City, and currently has clinics in London, Birmingham, Manchester and Stockholm. The scan costs £299 in the U.K. and 2,750 SEK in Sweden. Neko Health has not announced the price in the U.S. yet, but told MedCity News that it will be “commensurate with the U.K. costs.”
Since launching in 2023, over 350,000 people have registered for a Neko Health Scan, and 100,000 people have received one. Neko Health reported that three in four returning members whose earlier scans identified severe or life-threatening conditions saw their condition improve by their next scan.
“This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts. With this round, we’re taking that mission to the US for the first time, while continuing to invest in the research and technology that make prevention possible at scale,” said Hjalmar Nilsonne, Neko Health co-founder and CEO, in a statement. “The clearest proof is in our members: the vast majority of our members return after their first scan, and when they do, their health markers move in the right direction.”
Ultimately, Neko Health aims to accelerate the healthcare system’s shift toward preventive care.
“Neko Health’s ultimate goal is to fundamentally redesign healthcare from a system that treats illness to one that preserves health,” a Neko Health spokesperson said. “The company isn’t simply trying to build a better health scan—it’s trying to create a new model of healthcare centered on prevention, continuous monitoring, and early intervention.”
Photo: Richard Drury, Getty Images
